BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 30064664)

  • 1. Seeking Convergence and Cure with New Myeloma Therapies.
    Choudhry P; Galligan D; Wiita AP
    Trends Cancer; 2018 Aug; 4(8):567-582. PubMed ID: 30064664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting the Immune Niche within the Bone Marrow Microenvironment: The Rise of Immunotherapy in Multiple Myeloma.
    Podar K; Jager D
    Curr Cancer Drug Targets; 2017; 17(9):782-805. PubMed ID: 28201977
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging small molecule approaches to enhance the antimyeloma benefit of proteasome inhibitors.
    Driscoll JJ; Brailey M
    Cancer Metastasis Rev; 2017 Dec; 36(4):585-598. PubMed ID: 29052093
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of Immunotherapy in Targeting the Bone Marrow Microenvironment in Multiple Myeloma: An Evolving Therapeutic Strategy.
    Chung C
    Pharmacotherapy; 2017 Jan; 37(1):129-143. PubMed ID: 27870103
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Novel Immunotherapies for Multiple Myeloma.
    D'Agostino M; Boccadoro M; Smith EL
    Curr Hematol Malig Rep; 2017 Aug; 12(4):344-357. PubMed ID: 28819882
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel targeted therapies and combinations for the treatment of multiple myeloma.
    Agarwal A; Mahadevan D
    Cardiovasc Hematol Disord Drug Targets; 2013 Mar; 13(1):2-15. PubMed ID: 22882073
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Monoclonal antibody therapy in multiple myeloma: where do we stand and where are we going?
    Thanendrarajan S; Davies FE; Morgan GJ; Schinke C; Mathur P; Heuck CJ; Zangari M; Epstein J; Yaccoby S; Weinhold N; Barlogie B; van Rhee F
    Immunotherapy; 2016; 8(3):367-84. PubMed ID: 26888183
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Contemporary drug therapies for multiple myeloma.
    de la Puente P; Azab AK
    Drugs Today (Barc); 2013 Sep; 49(9):563-73. PubMed ID: 24086952
    [TBL] [Abstract][Full Text] [Related]  

  • 9. CD38 Monoclonal Antibody Therapies for Multiple Myeloma.
    Wong SW; Comenzo RL
    Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):635-45. PubMed ID: 26443328
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Coinhibitory Molecule PD-1 as a Therapeutic Target in the Microenvironment of Multiple Myeloma.
    Atanackovic D; Luetkens T; Radhakrishnan S; Kroger N
    Curr Cancer Drug Targets; 2017; 17(9):839-845. PubMed ID: 28875836
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunotherapy for the treatment of multiple myeloma.
    Jung SH; Lee HJ; Vo MC; Kim HJ; Lee JJ
    Crit Rev Oncol Hematol; 2017 Mar; 111():87-93. PubMed ID: 28259300
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Anti-body building: The exercise of advancing immune based myeloma therapies.
    Richter J; Thibaud S
    Blood Rev; 2021 Jul; 48():100789. PubMed ID: 33384171
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD38 as an immunotherapeutic target in multiple myeloma.
    Bonello F; D'Agostino M; Moscvin M; Cerrato C; Boccadoro M; Gay F
    Expert Opin Biol Ther; 2018 Dec; 18(12):1209-1221. PubMed ID: 30394809
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Is immunotherapy here to stay in multiple myeloma?
    Rodríguez-Otero P; Paiva B; Engelhardt M; Prósper F; San Miguel JF
    Haematologica; 2017 Mar; 102(3):423-432. PubMed ID: 28082344
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The landscape of new drugs in extranodal NK/T-cell lymphoma.
    Wang L; Li LR; Zhang L; Wang JW
    Cancer Treat Rev; 2020 Sep; 89():102065. PubMed ID: 32653806
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current treatment options of T cell-associated immunotherapy in multiple myeloma.
    Liu H; Pan Y; Meng S; Zhang W; Zhou F
    Clin Exp Med; 2017 Nov; 17(4):431-439. PubMed ID: 28120217
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunopathogenesis and immunotherapy of multiple myeloma.
    Tamura H
    Int J Hematol; 2018 Mar; 107(3):278-285. PubMed ID: 29368256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Multiple Myeloma Drug Pipeline-2018: A Review of Small Molecules and Their Therapeutic Targets.
    Abramson HN
    Clin Lymphoma Myeloma Leuk; 2018 Sep; 18(9):611-627. PubMed ID: 30001985
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunologic approaches for the treatment of multiple myeloma.
    Rasche L; Weinhold N; Morgan GJ; van Rhee F; Davies FE
    Cancer Treat Rev; 2017 Apr; 55():190-199. PubMed ID: 28431262
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.